Nilotinib monohydrochloride monohydrate is primarily used in the treatment of chronic myeloid leukemia (CML), a type of blood cancer. It is specifically prescribed for patients who are resistant or intolerant to prior therapy, including imatinib. The compound works by inhibiting the BCR-ABL tyrosine kinase, an abnormal enzyme produced by cancer cells that promotes their growth and proliferation. By blocking this enzyme, it helps to slow down or stop the progression of the disease. It is often administered orally and is part of targeted therapy, offering a more precise approach compared to traditional chemotherapy. Regular monitoring of patients is essential to manage potential side effects and ensure the effectiveness of the treatment.